FDA Actions vs Clinical Trials
Side-by-side coverage analysis for FDA Actions and Clinical Trials.
This comparison applies the same classification pipeline used across every story on this site, which scores each linked entity at a minimum 35 percent relevance threshold before it is surfaced. According to our editorial methodology, reviewed July 2026, this follows multi-source corroboration standards recommended by journalism research bodies such as the Reuters Institute for the Study of Journalism.
FDA Actions
Approvals, rejections, priority reviews
- Stories
- 73
- Avg Impact
- 6.6/10
- Dominant Tone
- Positive
- Latest
- 2d ago
Clinical Trials
Phase I-III results, trial design
- Stories
- 104
- Avg Impact
- 6.5/10
- Dominant Tone
- Positive
- Latest
- 1d ago
Recent Headlines
FDA Actions
- 3 in 5 abortions use mifepristone as 5th Circuit weighs limits
- FDA Drug Chief to Oversee 3 Psychedelic Candidates: Psilocybin, MDMA, LSD
- FDA Names 4 Center Directors as Psychedelics Reviews Take Shape
- Mifepristone in 60% of U.S. abortions faces FDA rule fight in 5th Circuit
- Endometriosis tests advance abroad while U.S. lags for 1 in 10 women
- Rasonque Approved: KRAS Inhibitor Doubles Survival to 13.2 Months
- ICP DAS-BMP TPU with 20-40% Barium Sulfate Targets Implantable Devices
- Druckenmiller's Q2 RYTM Bet Targets 2 FDA Nods in Rare Obesity
- Zeon's FDA FSMA + NSF 21 CFR Part 111 cGMP Boost India CDMO Credibility
- Opdivo's 1/12th Dose Shows Efficacy in Indian Study, Sparking FDA Label Debate
Clinical Trials
- Semaglutide real-world data show 40% fewer asthma attacks in ERS study
- Nuvation Bio's 1 Approved Drug vs Cramer's 5-Word 'Pure Spec' Call
- CyPath Lung: 92% Sensitivity, 99% NPV Drive bioAffinity's Surveillance Pivot
- HELIOS-B: vutrisiran benefit consistent in 259 tafamidis users
- Aprea's 28 Issued Patents Shield WEE1/ATR Pipeline as APR-1051 Advances
- Fecal transplant trial: 33M allergy patients gain new hope
- Neridronate Phase 3 Backed by $150M Merger and Financing
- Telix H1: $68M R&D, ProstACT Global Advances Late-Stage Pipeline
- Lung and stomach cancer waits jump 12–14 days, raising progression risk
- HLA double match: £1.37M NHS aim to cut 100 kidney rejections